Sarepta Therapeutics (SRPT) Tops Q4 EPS by 4c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sarepta Therapeutics (SRPT) PT Raised to $96 at Nomura/Instinet on 4Q Beat; 'Pipeline Registration Path & DMD Gene Therapies Emerge in 2018'
March 2, 2018 6:21 AM ESTNomura/Instinet raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $84.00) while maintaining a Buy rating, following the company's fourth quarter earnings report.
Analyst Christopher Marai notes a positive outlook on the shares, as SRPT reported fourth quarter earning per share and... More
